|
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
May 23, 2019
Viking Therapeutics, Inc.
(Exact Name of Registrant as Specified in Charter)
|
Delaware
|
|
001-37355
|
|
46-1073877
|
|
(State or Other Jurisdiction of
Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
12340 El Camino Real, Suite 250, San Diego, California 92130
(Address of Principal Executive Offices) (Zip Code)
Registrant’s telephone number, including area code:
(858) 704-4660
N/A
(Former Name, or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Securities registered pursuant to Section 12(b) of the Act
|
|
|
|
|
Title of Each Class
|
|
Trading Symbol
|
Name of Each Exchange on Which Registered
|
|
Common Stock, par value $0.00001 per share
|
|
VKTX
|
The Nasdaq Stock Market LLC
|
|
Warrants to purchase Common Stock, par value $0.00001 per share
|
|
VKTXW
|
The Nasdaq Stock Market LLC
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933
(§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
In this report, “Viking Therapeutics,” “Viking,” “Company,” “we,” “us” and “our” refer to Viking Therapeutics, In
c.
Item 5.07. Submission of Matters to a Vote of Security Holders.
The 2019 Annual Meeting of Stockholders (the “Annual Meeting”) of the Company was held on May 23, 2019. At the Annual Meeting, the Company’s stockholders elected the Class I director nominees of the Company and ratified the selection of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2019 (together, the “Proposals”). Each Proposal is described in detail in the Company’s definitive proxy statement for the Annual Meeting that was filed with the U.S. Securities and Exchange Commission on April 5, 2019. As of April 1, 2019, the record date for the Annual Meeting, 72,027,657 shares of the Company’s common stock were issued and outstanding. The final votes on the Proposals presented at the Annual Meeting are as follows:
Proposal 1. Election of Class I Director Nominees
Matthew W. Foehr and Charles A. Rowland, Jr. were each elected as Class I directors at the Annual Meeting to serve until the Company’s 2022 Annual Meeting of Stockholders, and until his respective successor is duly elected and qualified. The final voting results were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Director Nominee
|
|
Votes For
|
|
Votes Withheld
|
|
Broker Non-Votes
|
|
Matthew W. Foehr
|
|
20,855,118
|
|
5,041,676
|
|
31,117,210
|
|
Charles A. Rowland, Jr.
|
|
18,612,432
|
|
7,284,362
|
|
31,117,210
|
Proposal 2. Ratification of the Selection of the Company’s Independent Registered Public Accounting Firm
The Company’s stockholders ratified the selection by the Audit Committee of the Board of Directors of the Company of Marcum LLP as the Company’s independent registered public accounting firm for its fiscal year ending December 31, 2019. The final voting results were as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Votes For
|
|
Votes Against
|
|
Abstentions
|
|
Broker Non-Votes
|
|
55,684,813
|
|
999,154
|
|
330,037
|
|
0
|
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
|
|
|
|
|
Viking Therapeutics, Inc.
|
|
|
|
|
|
Date:
May 23, 2019
|
By:
|
/s/ Brian Lian, Ph.D.
|
|
|
|
Brian Lian, Ph.D.
|
|
|
|
President and Chief Executive Officer
|
|
|
|
(Principal Executive Officer)
|
| 